Document:

Exhibit 10.59 

 

LICENSE AGREEMENT

 

This
License Agreement (“Agreement”) is made this ____ day of April, 2021 (the “Effective Date”), by and among
Pharmalectin, Inc. (“Licensee”), a Delaware corporation, and Bioxytran, Inc. (“BIXT”), a Nevada corporation.

 

RECITALS:

 

A.
David Platt (“Platt”) has contributed to BIXT the “Modified Pectin” (as defined below) and (as defined
below) that has therapeutic use against COVID and Influenza, together with certain patents and knowhow relating thereto.

 

B.
BIXT desires to grant, and Licensee desires to obtain, an exclusive, worldwide, license to the “Subject Technology”
(as defined below) in certain very specific fields of use in accordance with all of the terms of this Agreement.

 

C.
Licensee will provide funds to, and assist, BIXT in modifying the Modified Pectin and developing a therapeutic compound for treatment
of COVID and Influenza.

 

D.
BIXT is an Affiliate (as defined below) of Licensee, and BIXT and Licensee desire to enter into an arm’s length relationship
in connection with the licensing of the Subject Technology so this Agreement has been independently reviewed by Platt and he has
recommended to the Board of Directors of BIXT to enter into this Agreement.

 

NOW,
THEREFORE, the parties hereto agree as follows:

 

ARTICLE 1

Definitions

 

As
used herein, the following definitions and terms shall have the designated meanings:

 

1.1.
“Action” shall mean any claim, action, suit or proceeding, whether civil or criminal, or in law or equity and
including any arbitration.

 

1.2.
“Affiliate” of any entity shall mean any other entity that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the first entity. Control shall mean owning at least 50 percent
of the total voting power of the entity.

 

1.3.
“Confidential Information” shall mean means and includes all technical information, inventions, developments,
discoveries, software, know-how, methods, techniques, formulae, data, processes and other proprietary ideas, whether or not patentable
or copyrightable, regardless, whether the disclosing party identifies such information as confidential or proprietary, in the case
of Licensee relating in any manner to Licensee’s compounds, or in the case of BIXT, related to the Modified Pectin, at the
time it is delivered or communicated to a party (the “receiving party”) by a party (the “disclosing party”)
or their respective employees, agents or consultants, excluding any information which:

 

(a)
is or becomes publicly available through no fault of the receiving party; or

 

(b)
is disclosed to the receiving party by a third party who, to the best of the receiving party’s knowledge, is lawfully in
possession of the same and has the right to make such disclosure; or

 

    	1 

    	 

    

(c)
has been independently developed by the receiving party without reference to the information disclosed to the receiving party by
the disclosing party or its employees, agents or consultants.

 

1.4.
“Expiration” or “Expired” shall mean with respect to a particular patent, the patent’s
expiration, abandonment, cancellation, disclaimer, award to another party other than BIXT or an Affiliate of BIXT in an interference
proceeding, or declaration of invalidity or unenforceability of all claims thereof by a court or other authority of competent jurisdiction
(including a re-examination or reissue proceeding) from which no further appeal has or can be taken. References to an “Unexpired”
patent shall mean a patent that has not Expired.

 

1.5.
“Field of Use” shall mean any applications using the Modified Pectin technology, or any modified, improved or
derivative product based on the Modified Pectin, for exclusive use with treatment of COVID and Influenza.

 

1.6.
“Law” shall mean any law, regulation, rule, ordinance or governmental regulation or guideline or any judicial,
administrative or arbitration, order or award, judgment, writ, injunction or decree which is applicable to a person or by which
a person is bound.

 

1.7.
“Licensed Products” shall mean Modified Pectin, any manufactured, modified, improved or derivative product based
on the Modified Pectin as used by Licensee within the purposes set forth in the Field of Use.

 

1.9.
“Product Liability Claims” shall mean claims for personal injury or death based on alleged breach of product
warranty, strict liability in tort, or negligent product design or manufacture.

 

1.10.
“Subject Technology” shall mean (i) the Modified Pectin, (ii)  the issued patents, and patents arising
out of the patent applications, listed on Exhibit A hereto, (iii) all reissues, continuations, continuations-in-part, extensions,
reexaminations, and foreign counterparts thereof, (vi) all inventions, disclosures, trade secrets and know-how owned by BIXT
prior to and subsequent to the date of this Agreement which relate specifically to the Modified Pectin and (v) those improvements,
enhancements and modifications to any technology set forth in subclauses (i) – (iv) of this paragraph and as additionally
identified in Section 2.6(b) hereof. The Subject Technology does not include any trademarks, trade names or service marks
owned or used by BIXT.

 

1.12.
“Territory” shall mean the entire world.

 

1.13.
“Modified Pectin” shall mean the Modified Pectin developed by BIXT and any modification thereof for the intended
for treatment within the Field of Use.

 

ARTICLE 2

License; Term
and Termination

 

2.1. License
Grant. Subject to the terms and provisions hereof, BIXT hereby irrevocably grants (subject to the terms of this Agreement)
a royalty-free and exclusive license to the Subject Technology within the Field of Use throughout the Territory and Licensee shall
pay BIXT the licensing fee set forth in Section 3.1 hereof.

 

2.2. Term
of License. Unless otherwise terminated under provisions of this Article 2, this Agreement and the licenses granted under Section
2.1 shall continue in perpetuity.

 

    	2 

    	 

    

 

2.3. Termination.

 

(a)
If Licensee materially breaches any of the material terms, conditions or agreements of this Agreement, then BIXT may terminate
this Agreement, at its option, and without prejudice to any of its other legal and equitable rights and remedies, including, but
not limited to, seeking monetary damages and/or an injunction, by giving Licensee Thirty (30) days’ notice in writing, particularly
specifying the breach. Such notice of termination shall not be effective if Licensee cures the specified breach within such Thirty
(30) day period. During such 30-day period, one or more executive officers of each party (meaning for purposes hereunder any
vice president or higher level officer and in the case of BIXT, Platt) shall meet or correspond to discuss such alleged breach
and/or attempted cure thereof, and use their best efforts to resolve any dispute between the parties with respect thereto; provided that
if any such dispute is not resolved to BIXT’s reasonable satisfaction, then BIXT may terminate this Agreement without prejudice
to any of its other legal and equitable rights and remedies including, but not limited to, seeking monetary damages and/or an injunction.
Licensee may terminate this Agreement at any time in its discretion upon Thirty (30) days’ prior written notice. Termination
of this Agreement shall not result in any refund to Licensee of any consideration previously paid to BIXT. The parties acknowledge
that, with respect to any other breaches by Licensee of the terms, conditions or agreements of this Agreement, BIXT may pursue
its full legal and equitable rights and remedies against Licensee, including, but not limited to, seeking monetary damages and/or
an injunction.

 

(b)
Either party may, by written notice to the other party (which notice shall be effective upon receipt), terminate this Agreement
in the event that such other party becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or
receivership or otherwise loses legal control of its business.

 

(c)
The parties acknowledge and agree that all rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed
to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101(52) of the Bankruptcy Code, and that each party, as a licensee hereunder, shall retain and may fully
exercise all of its rights and elections under the Bankruptcy Code.

 

2.5. Delivery
and Return of Confidential Information. Upon termination of this Agreement or the licenses granted hereunder as provided herein,
each party shall within 30 days of such termination return to the other party all of the other party’s Confidential Information.
Notwithstanding the foregoing each party shall have the right to retain one copy of such other party’s Confidential Information
in its legal department files for archival purposes only.

 

2.6. Know-How
Transfer; Improvements; Access to BIXT’s Employees and Consultant.

 

(a)
Promptly after the Effective Date, BIXT shall provide to Licensee copies of all tangible Subject Technology not previously disclosed
to Licensee.

 

(b)
Upon reasonable notice by Licensee to BIXT, BIXT will provide the services, and make available Platt and the scientific staff of
BIXT to meet with Licensee to disclose to Licensee on BIXT’s behalf those trade secrets and know-how included within the
Subject Technology to allow Licensee to better understand and practice the inventions disclosed therein and to make improvements
thereon in order to provide with and Modified Pectin within the Field of Use by Licensee.

 

(c)
BIXT shall provide written waivers from any non-compete and confidentiality obligations of Platt and such BIXT employees to the
extent necessary to permit the disclosures and consulting contemplated under Section 2.6(b).

 

    	3 

    	 

    

ARTICLE 3

License Fee

 

3.1. License
Fee. Licensee shall pay Grantor a licensing fee consisting on one side of a non-dilutive 50% of shares in Pharmalectin, Inc.,
and on the other side a Management Fee of 25% of R&D expenses paid by the Licensee, after deduction of paid G&A expenses.
The Management Fee can optionally be converted to equity at a price of $1.00/share. If Pharmalectin, Inc. does not raise sufficient
financing for the development and clinical approvals necessary to commercialize the therapeutic for its intended use on the major
markets (U.S., E.U. and India) as by December 31, 2021, the License can optionally be repurchased at invested capital and thereby
be returned to Grantor along with all potential rights in any development and clinical approvals and Trademaks by the Licensee
the Grantor will be reimbursed for any reasonable expenses related hereto.

 

Licensee shall pay
Grantor for the development efforts set forth in Section 2.6(b) hereof to improve the Subject Technology at cost and reimburse
Grantor for any reasonable travel and lodging expenses.

 

ARTICLE 4

Additional Obligations

 

4.1. Restrictions
on Use. Licensee will use all reasonable efforts to ensure that all Licensed Products designed, developed, manufactured or
sold by Licensee are not used outside of the Field of Use.

 

4.2. Confidentiality.
The parties acknowledge that the patent applications listed in Exhibit A hereto, the inventions claimed therein, and all trade
secrets and know-how included within the Subject Technology constitute “Confidential Information” of BIXT, subject
to the exceptions set forth in Section 1.3. Each party agrees not to disclose or use any of the other party’s Confidential
Information except as expressly permitted in connection with the exercise of its rights hereunder. Each party shall not disclose
the other party’s Confidential Information to any employee or consultant unless such employee or consultant is obligated
under a confidentiality agreement to maintain such other party’s Confidential Information in strict confidence, and not to
use such information other than, in accordance with the terms of this Agreement. Each party agrees to hold the other party’s
Confidential Information in strict confidence and treat it with not less than the same degree of care to avoid disclosure as such
party employs with respect to its own information of like importance.

 

4.3. Infringement
by Third Party. Licensee shall promptly notify BIXT and BIXT shall promptly notify Licensee in writing if BIXT or Licensee
knows or has reason to believe that the rights of BIXT or Licensee relating to the Subject Technology are being infringed by a
third party.

 

ARTICLE 5

Intellectual
Property

 

5.1. No
Representation or Warranty. EXCEPT AS PROVIDED IN ARTICLE 6, BIXT MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO
THE SUBJECT TECHNOLOGY OR ANY LICENSED PRODUCTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, PATENTABILITY, PATENT VALIDITY, NON-INFRINGEMENT, OR WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.

 

    	4 

    	 

    

 

5.2. Control
of Subject Technology.

 

(a)
BIXT shall have the sole and exclusive right, in BIXT’s absolute discretion and at its sole expense, to prosecute any alleged
infringement, misappropriation or misuse of the Subject Technology: (i) outside the Field of Use, and shall retain all proceeds
from prosecution up to the amount of any expenses of prosecution and investigation as well as retain all proceeds from prosecution
in excess of expenses of prosecution and investigation, and (ii) in the Field of Use, and shall retain all proceeds from prosecution
up to the amount of any expenses of prosecution and investigation and shall retain fifty percent (50%) of all proceeds from
such prosecution in excess of expenses of prosecution and investigation and shall pay the balance to the Licensee. If BIXT decides
at any time not to commence or continue to prosecute any alleged infringement, misappropriation or misuse of the Subject Technology
in the Field of Use, it shall so notify Licensee in writing, and Licensee shall have the right, in its absolute discretion, to
commence or continue such prosecution. If Licensee chooses to commence or continue such prosecution, Licensee shall fully fund
such prosecution at its sole expense and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution
and investigation as well as retain one hundred percent (100%) of all proceeds from prosecution in excess of expenses of prosecution
and investigation. At the request of the party prosecuting a suit, the other party shall cooperate with the party prosecuting the
suit in any such legal action either party may prosecute or defend under this Section 5.2(a).

 

5.3. Indemnification.

 

(a)
Licensee shall indemnify, defend and hold harmless BIXT and BIXT’s respective officers, directors, shareholders, employees
and agents (collectively, all such indemnitees are referred to in this Section 5.3(a) as “BIXT Indemnitees”) against
and in respect of any and all claims, demands, losses, obligations, liabilities, damages (and including without limitation compensatory
and punitive damages), deficiencies, Actions, settlements, judgments, costs and expenses which the BIXT Indemnitees may incur or
suffer or with which it may be faced (including reasonable costs and legal fees incident thereto or in seeking indemnification
therefor) arising out of or based upon (i) any Product Liability Claims resulting from development, manufacture, use, or sale
of any Licensed Product by Licensee or any sublicensee or third party permitted under Section 2.2, or (ii) any breach
of this Agreement by Licensee.

 

(b)
BIXT shall indemnify and hold harmless Licensee and its respective officers, directors, shareholders, employees and agents (collectively,
all such indemnitees are referred to in this Section 5.3(b) as “Licensee Indemnitees”) against and in respect
of any and all demands, losses, obligations, liabilities, damages (and including without limitation compensatory and punitive damages),
deficiencies, Actions, settlements, judgments, costs and expenses which the Licensee Indemnitees may incur or suffer or with which
it may be faced (including reasonable costs and legal fees incident thereto or in seeking indemnification therefor) arising out
of or based upon any breach of this Agreement by BIXT.

 

5.4. Limitation
on Liability. In no event shall BIXT’s liability under this Agreement exceed the amount actually paid to BIXT by Licensee
as a licensing fee regardless of the form or basis of the action or claim, except with respect to (i) the grant by BIXT of
any license under the Subject Technology to make, have made, use or sell Modified Pectin in the Field of Use that are Licensed
Products, in the Territory, to any third party; (ii) the manufacture, use or sale by BIXT of Modified Pectin in the Field
of Use that are Licensed Products, in the Territory; (iii) breach by BIXT of its obligations of non-disclosure and non-use
under Section 4.2, or (iv) breach by BIXT of its representations and warranties under Article 6.

 

    	5 

    	 

    

 

5.5. Licensee
Regulatory Interaction Rights. Notwithstanding Section 5.2 above, interaction with the regulatory agencies in any country,
including, without limitation the FDA, concerning Modified Pectin of Licensee in the Field of Use shall be exclusively conducted
by Licensee and Licensee shall be the official company sponsor. Subject to Section 5.3(a) hereof, Licensee shall have complete
authority to act as Licensee, in its sole discretion, deems appropriate with respect to any such regulatory matter.

 

5.7. Trademark.
Nothing in this Agreement shall be deemed to grant to Licensee any right to use the trademark “BIXT”, the BIXT corporate
logo, or any other trademark owned by BIXT or its Affiliates.

 

ARTICLE 6

Representations &
Warranties

 

6.1. Organization.
Each party represents and warrants to the other party that such party is a corporation duly organized, validly existing, and in
good standing under the laws of the jurisdiction of its incorporation.

 

6.2. Authorization
of Transaction. Each party represents and warrants to the other party that it has full power and authority (including full
corporate power and authority) to execute and deliver this Agreement and to perform its obligations hereunder. All necessary corporate
proceedings (including any necessary approval by the board of directors) have been taken by such party to duly authorize the execution,
delivery, and performance of this Agreement by such party. This Agreement constitutes the valid and legally binding obligation
of such party, enforceable against such party in accordance with its terms and conditions.

 

6.3. No
Conflicts. BIXT represents and warrants to Licensee that it has not entered into any inconsistent prior obligations concerning
the Subject Technology that would prevent Licensee from exercising the rights being licensed to it hereunder.

 

6.4. No
Claims. BIXT represents and warrants to it has not received written notification from a third party that the manufacture, use,
importation or sale of the License Products under the license granted herein under the Subject Technology will infringe any patents,
copyrights, trade secrets or any other intellectual property rights of any third parties.

 

6.5. Rights
to License. BIXT represents and warranties that it has all rights necessary to enter into this Agreement with Licensee, including,
without limitation, all licenses and assignments from Platt of the Subject Technology required to permit this license to Licensee
under this Agreement.

 

ARTICLE 7

Miscellaneous

 

7.1. Assignment.
Either party may assign or otherwise transfer its rights and obligations under this Agreement to any successor in interest (by
merger, share exchange, combination or consolidation of any type, operation of Law, purchase or otherwise), provided that such
assignee or successor agrees to be bound by the terms hereof, and provided further that in the event of such an assignment by Licensee,
Licensee’s consulting agreement with [*], if any, pursuant to Section 2.6 and Licensee’s right of notice pursuant
to Section 2.7 shall terminate effective upon such transfer and assignment. Except as set forth above, Licensee may not assign
or otherwise transfer its rights and obligations under this Agreement and any attempt to so assign or otherwise transfer its rights
and obligations under this Agreement shall represent a breach of the Agreement.

 

    	6 

    	 

    

 

7.2. Entire
Agreement. This Agreement, together with the Exhibits hereto, the Investor Agreement and the Investors’ Rights Agreement,
constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all previous proposals
or agreements, oral or written, and all negotiations, conversations or discussions heretofore had between the parties related to
the subject matter of this Agreement.

 

7.3. Survival.
Articles 4 and 7 and Section 5.3 shall survive termination or expiration of this Agreement for any reason and continue thereafter
in full force and effect.

 

7.4. Waiver,
Discharge, etc. This Agreement may not be released, discharged, abandoned, changed or modified in any manner, except by an
instrument in writing signed on behalf of each of the parties to this Agreement by their duly authorized representatives. The failure
of either party to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any
such provision, nor in any way to affect the validity of this Agreement or any part of it or the right of either party after any
such failure to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to be a waiver of
any other or subsequent breach.

 

7.5. Execution
in Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
agreement, and shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the
other party.

 

7.6. Titles
and Headings: Construction. The titles and headings to Sections herein are inserted for the convenience of reference only and
are not intended to be a part of or to affect the meaning or interpretation of this Agreement. This Agreement shall be construed
without regard to any presumption or other rule requiring construction hereof against the party causing this Agreement to be drafted.

 

7.7. Benefit.
Nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties to this Agreement or
their respective permitted successors or assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

7.8. Notices.
All notices or other communications to a party required or permitted hereunder shall be in writing and shall be delivered personally,
overnight mail or by telecopy (receipt confirmed) to such party (or, in the case of an entity, to an executive officer of such
party) or shall be given by certified mail, postage prepaid with return receipt requested, addressed as follows:

 

if to Licensee, to:

 

Pharmalectin, Inc.

233 Needham St., Ste
300,

Newton, MA 02464

Att: Ola Soderquist

 

and if to BIXT, to:

 

Bioxytran, Inc.

233 Needham St., Ste
300,

Newton, MA 02464

Att: David Platt

 

    	7 

    	 

    

 

Licensee or BIXT may
change their respective above-specified recipient and/or mailing address by notice to the other party given in the manner herein
prescribed. All notices shall be deemed given on the day when actually delivered as provided above (if delivered personally or
by telecopy) or on the day shown on the return receipt (if delivered by mail).

 

7.9. Severability.
If any provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining provisions shall nonetheless
be enforceable according to their terms. Further, if any provision is held to be overbroad as written, such provision shall be
deemed amended to narrow its application to the extent necessary to make the provision enforceable according to applicable Law
and shall be enforced as amended.

 

7.10. Governing
Law. This Agreement shall be construed in accordance with Massachusetts law, excluding its choice of law provisions.

 

[Signature Page Follows]

    	8 

    	 

    

 

IN WITNESS WHEREOF,
each of the parties has caused this License Agreement to be executed in the manner appropriate to each, effective as of the date
first above written.

 

 

	
        GRANTOR:

         
	 	
        LICENSEE:

         

	
        
BioXyTran, Inc.,

a Nevada corporation

         
	 	
        Pharmalectin, Inc.,

        a Delaware corporation

         

	 	 	 
	By: /s/
    David Platt_____________________	 	By: /s/Ola
    Soderquist_________________
	Name:David Platt                                                  	 	Name:Ola Soderquist                                        
	Title:CEO                                                                	 	Title:CFO                                                             

 

 

 

    	9 

    	 

    

Exhibit A

 

Subject Technology

 

 

 

APPLICATION INFORMATION

Application Number: unassigned

Application Type: Provisional

Subject Matter: Utility

Title: Galactomannans for Treatment of
SARS COV2 / COVID-19

Attorney Docket Number:: MDX-P03-01

Small Entity: Yes

 

    	10Exhibit 10.60 

 

LICENSE AGREEMENT

 

This
License Agreement (“Agreement”) is made this ____ day of April, 2021 (the “Effective Date”), by and among
Pharmalectin, Inc. (“Licensee”), a Delaware corporation, and NDPD Pharma, Inc. (“NDPD”), a Delaware corporation.

 

RECITALS:

 

A. David
Platt (“Platt”) has contributed to NDPD the “Hydrolyzed Galactomannan” (as defined below) and (as defined
below) that has therapeutic use against COVID-19, together with certain patents and knowhow relating thereto.

 

B. NDPD
desires to grant, and Licensee desires to obtain, an exclusive, worldwide, license to the “Subject Technology” (as
defined below) in certain very specific fields of use in accordance with all of the terms of this Agreement.

 

C. Licensee
will provide funds to, and assist, NDPD in modifying the Hydrolyzed Galactomannan and developing a therapeutic compound for treatment
of COVID-19.

 

D. NDPD
is an Affiliate (as defined below) of Licensee, and NDPD and Licensee desire to enter into an arm’s length relationship in
connection with the licensing of the Subject Technology so this Agreement has been independently reviewed by Platt and he has recommended
to the Board of Directors of NDPD to enter into this Agreement.

 

NOW,
THEREFORE, the parties hereto agree as follows:

 

ARTICLE 1

Definitions

 

As used
herein, the following definitions and terms shall have the designated meanings:

 

1.1.
“Action” shall mean any claim, action, suit or proceeding, whether civil or criminal, or in law or equity and
including any arbitration.

 

1.2.
“Affiliate” of any entity shall mean any other entity that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the first entity. Control shall mean owning at least 50 percent
of the total voting power of the entity.

 

1.3.
“Confidential Information” shall mean means and includes all technical information, inventions, developments,
discoveries, software, know-how, methods, techniques, formulae, data, processes and other proprietary ideas, whether or not patentable
or copyrightable, regardless, whether the disclosing party identifies such information as confidential or proprietary, in the case
of Licensee relating in any manner to Licensee’s compounds, or in the case of NDPD, related to the Hydrolyzed Galactomannan,
at the time it is delivered or communicated to a party (the “receiving party”) by a party (the “disclosing party”)
or their respective employees, agents or consultants, excluding any information which:

 

(a) is
or becomes publicly available through no fault of the receiving party; or

 

(b) is
disclosed to the receiving party by a third party who, to the best of the receiving party’s knowledge, is lawfully in possession
of the same and has the right to make such disclosure; or

 

    	1 

    	 

    

(c) has
been independently developed by the receiving party without reference to the information disclosed to the receiving party by the
disclosing party or its employees, agents or consultants.

 

1.4.
“Expiration” or “Expired” shall mean with respect to a particular patent, the patent’s
expiration, abandonment, cancellation, disclaimer, award to another party other than NDPD or an Affiliate of NDPD in an interference
proceeding, or declaration of invalidity or unenforceability of all claims thereof by a court or other authority of competent jurisdiction
(including a re-examination or reissue proceeding) from which no further appeal has or can be taken. References to an “Unexpired”
patent shall mean a patent that has not Expired.

 

1.5.
“Field of Use” shall mean any applications using the Hydrolyzed Galactomannan technology, or any modified, improved
or derivative product based on the Hydrolyzed Galactomannan, for exclusive use with treatment of COVID-19.

 

1.6.
“Law” shall mean any law, regulation, rule, ordinance or governmental regulation or guideline or any judicial,
administrative or arbitration, order or award, judgment, writ, injunction or decree which is applicable to a person or by which
a person is bound.

 

1.7.
“Licensed Products” shall mean Hydrolyzed Galactomannan, any manufactured, modified, improved or derivative
product based on the Hydrolyzed Galactomannan as used by Licensee within the purposes set forth in the Field of Use.

 

1.9.
“Product Liability Claims” shall mean claims for personal injury or death based on alleged breach of product
warranty, strict liability in tort, or negligent product design or manufacture.

 

1.10.
“Subject Technology” shall mean (i) the Hydrolyzed Galactomannan, (ii)  the issued patents, and patents
arising out of the patent applications, listed on Exhibit A hereto, (iii) all reissues, continuations, continuations-in-part,
extensions, reexaminations, and foreign counterparts thereof, (vi) all inventions, disclosures, trade secrets and know-how
owned by NDPD prior to and subsequent to the date of this Agreement which relate specifically to the Hydrolyzed Galactomannan and
(v) those improvements, enhancements and modifications to any technology set forth in subclauses (i) – (iv) of this
paragraph and as additionally identified in Section 2.6(b) hereof. The Subject Technology does not include any trademarks,
trade names or service marks owned or used by NDPD.

 

1.12.
“Territory” shall mean the entire world.

 

1.13.
“Hydrolyzed Galactomannan” shall mean the Hydrolyzed Galactomannan developed by NDPD and any modification thereof
for the intended for treatment within the Field of Use.

 

ARTICLE 2

License; Term and Termination

 

2.1. License
Grant. Subject to the terms and provisions hereof, NDPD hereby irrevocably grants (subject to the terms of this Agreement)
a royalty-free and exclusive license to the Subject Technology within the Field of Use throughout the Territory and Licensee shall
pay NDPD the licensing fee set forth in Section 3.1 hereof.

 

2.2. Term
of License. Unless otherwise terminated under provisions of this Article 2, this Agreement and the licenses granted under Section
2.1 shall continue in perpetuity.

 

    	2 

    	 

    

 

2.3. Termination.

 

(a) If
Licensee materially breaches any of the material terms, conditions or agreements of this Agreement, then NDPD may terminate this
Agreement, at its option, and without prejudice to any of its other legal and equitable rights and remedies, including, but not
limited to, seeking monetary damages and/or an injunction, by giving Licensee Thirty (30) days’ notice in writing, particularly
specifying the breach. Such notice of termination shall not be effective if Licensee cures the specified breach within such Thirty
(30) day period. During such 30-day period, one or more executive officers of each party (meaning for purposes hereunder any
vice president or higher level officer and in the case of NDPD, Platt) shall meet or correspond to discuss such alleged breach
and/or attempted cure thereof, and use their best efforts to resolve any dispute between the parties with respect thereto; provided that
if any such dispute is not resolved to NDPD’s reasonable satisfaction, then NDPD may terminate this Agreement without prejudice
to any of its other legal and equitable rights and remedies including, but not limited to, seeking monetary damages and/or an injunction.
Licensee may terminate this Agreement at any time in its discretion upon Thirty (30) days’ prior written notice. Termination
of this Agreement shall not result in any refund to Licensee of any consideration previously paid to NDPD. The parties acknowledge
that, with respect to any other breaches by Licensee of the terms, conditions or agreements of this Agreement, NDPD may pursue
its full legal and equitable rights and remedies against Licensee, including, but not limited to, seeking monetary damages and/or
an injunction.

 

(b) Either
party may, by written notice to the other party (which notice shall be effective upon receipt), terminate this Agreement in the
event that such other party becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or receivership
or otherwise loses legal control of its business.

 

(c) The
parties acknowledge and agree that all rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed
to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as
defined under Section 101(52) of the Bankruptcy Code, and that each party, as a licensee hereunder, shall retain and may fully
exercise all of its rights and elections under the Bankruptcy Code.

 

2.5. Delivery
and Return of Confidential Information. Upon termination of this Agreement or the licenses granted hereunder as provided herein,
each party shall within 30 days of such termination return to the other party all of the other party’s Confidential Information.
Notwithstanding the foregoing each party shall have the right to retain one copy of such other party’s Confidential Information
in its legal department files for archival purposes only.

 

2.6. Know-How
Transfer; Improvements; Access to NDPD’s Employees and Consultant.

 

(a) Promptly
after the Effective Date, NDPD shall provide to Licensee copies of all tangible Subject Technology not previously disclosed to
Licensee.

 

(b) Upon
reasonable notice by Licensee to NDPD, NDPD will provide the services, and make available Platt and the scientific staff of NDPD
to meet with Licensee to disclose to Licensee on NDPD’s behalf those trade secrets and know-how included within the Subject
Technology to allow Licensee to better understand and practice the inventions disclosed therein and to make improvements thereon
in order to provide with and Hydrolyzed Galactomannan within the Field of Use by Licensee.

 

(c) NDPD
shall provide written waivers from any non-compete and confidentiality obligations of Platt and such NDPD employees to the extent
necessary to permit the disclosures and consulting contemplated under Section 2.6(b).

 

    	3 

    	 

    

ARTICLE 3

License Fee

 

3.1. License
Fee. Licensee shall pay Grantor a licensing fee of 1/3 of receipts from all future product revenue, fees and royalties for
ProLectin-M, or have the option to receive 1/3 of the company’s issued shares at time of exercise, in 3-year cashless warrants
at an exercise price of $1.00/share, or any pro-rated combination thereof. The Grantor will also have the right to 1 (one) Director’s
seat in the Licensees Board of Directors. If Pharmalectin, Inc. does not raise sufficient financing for the development and clinical
approvals necessary to commercialize the therapeutic for its intended use on the major markets (U.S., E.U. and India) as by December
31, 2021, the License can optionally be repurchased at invested capital and thereby be returned to Grantor along with all potential
rights in any development and clinical approvals and Trademaks by the Licensee the Grantor will be reimbursed for any reasonable
expenses related hereto.

 

Licensee shall pay Grantor
for the development efforts set forth in Section 2.6(b) hereof to improve the Subject Technology at cost and reimburse Grantor
for any reasonable travel and lodging expenses as well for his time for consulting the company in other matters.

 

ARTICLE 4

Additional Obligations

 

4.1. Restrictions
on Use. Licensee will use all reasonable efforts to ensure that all Licensed Products designed, developed, manufactured or
sold by Licensee are not used outside of the Field of Use.

 

4.2. Confidentiality.
The parties acknowledge that the patent applications listed in Exhibit A hereto, the inventions claimed therein, and all trade
secrets and know-how included within the Subject Technology constitute “Confidential Information” of NDPD, subject
to the exceptions set forth in Section 1.3. Each party agrees not to disclose or use any of the other party’s Confidential
Information except as expressly permitted in connection with the exercise of its rights hereunder. Each party shall not disclose
the other party’s Confidential Information to any employee or consultant unless such employee or consultant is obligated
under a confidentiality agreement to maintain such other party’s Confidential Information in strict confidence, and not to
use such information other than, in accordance with the terms of this Agreement. Each party agrees to hold the other party’s
Confidential Information in strict confidence and treat it with not less than the same degree of care to avoid disclosure as such
party employs with respect to its own information of like importance.

 

4.3. Infringement
by Third Party. Licensee shall promptly notify NDPD and NDPD shall promptly notify Licensee in writing if NDPD or Licensee
knows or has reason to believe that the rights of NDPD or Licensee relating to the Subject Technology are being infringed by a
third party.

 

ARTICLE 5

Intellectual Property

 

5.1. No
Representation or Warranty. EXCEPT AS PROVIDED IN ARTICLE 6, NDPD MAKES NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO
THE SUBJECT TECHNOLOGY OR ANY LICENSED PRODUCTS, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, PATENTABILITY, PATENT VALIDITY, NON-INFRINGEMENT, OR WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.

 

    	4 

    	 

    

 

5.2. Control
of Subject Technology.

 

(a) NDPD
shall have the sole and exclusive right, in NDPD’s absolute discretion and at its sole expense, to prosecute any alleged
infringement, misappropriation or misuse of the Subject Technology: (i) outside the Field of Use, and shall retain all proceeds
from prosecution up to the amount of any expenses of prosecution and investigation as well as retain all proceeds from prosecution
in excess of expenses of prosecution and investigation, and (ii) in the Field of Use, and shall retain all proceeds from prosecution
up to the amount of any expenses of prosecution and investigation and shall retain fifty percent (50%) of all proceeds from
such prosecution in excess of expenses of prosecution and investigation and shall pay the balance to the Licensee. If NDPD decides
at any time not to commence or continue to prosecute any alleged infringement, misappropriation or misuse of the Subject Technology
in the Field of Use, it shall so notify Licensee in writing, and Licensee shall have the right, in its absolute discretion, to
commence or continue such prosecution. If Licensee chooses to commence or continue such prosecution, Licensee shall fully fund
such prosecution at its sole expense and shall retain all proceeds from prosecution up to the amount of any expenses of prosecution
and investigation as well as retain one hundred percent (100%) of all proceeds from prosecution in excess of expenses of prosecution
and investigation. At the request of the party prosecuting a suit, the other party shall cooperate with the party prosecuting the
suit in any such legal action either party may prosecute or defend under this Section 5.2(a).

 

5.3. Indemnification.

 

(a) Licensee
shall indemnify, defend and hold harmless NDPD and NDPD’s respective officers, directors, shareholders, employees and agents
(collectively, all such indemnitees are referred to in this Section 5.3(a) as “NDPD Indemnitees”) against and
in respect of any and all claims, demands, losses, obligations, liabilities, damages (and including without limitation compensatory
and punitive damages), deficiencies, Actions, settlements, judgments, costs and expenses which the NDPD Indemnitees may incur or
suffer or with which it may be faced (including reasonable costs and legal fees incident thereto or in seeking indemnification
therefor) arising out of or based upon (i) any Product Liability Claims resulting from development, manufacture, use, or sale
of any Licensed Product by Licensee or any sublicensee or third party permitted under Section 2.2, or (ii) any breach
of this Agreement by Licensee.

 

(b) NDPD
shall indemnify and hold harmless Licensee and its respective officers, directors, shareholders, employees and agents (collectively,
all such indemnitees are referred to in this Section 5.3(b) as “Licensee Indemnitees”) against and in respect
of any and all demands, losses, obligations, liabilities, damages (and including without limitation compensatory and punitive damages),
deficiencies, Actions, settlements, judgments, costs and expenses which the Licensee Indemnitees may incur or suffer or with which
it may be faced (including reasonable costs and legal fees incident thereto or in seeking indemnification therefor) arising out
of or based upon any breach of this Agreement by NDPD.

 

5.4. Limitation
on Liability. In no event shall NDPD’s liability under this Agreement exceed the amount actually paid to NDPD by Licensee
as a licensing fee regardless of the form or basis of the action or claim, except with respect to (i) the grant by NDPD of
any license under the Subject Technology to make, have made, use or sell Hydrolyzed Galactomannan in the Field of Use that are
Licensed Products, in the Territory, to any third party; (ii) the manufacture, use or sale by NDPD of Hydrolyzed Galactomannan
in the Field of Use that are Licensed Products, in the Territory; (iii) breach by NDPD of its obligations of non-disclosure
and non-use under Section 4.2, or (iv) breach by NDPD of its representations and warranties under Article 6.

 

    	5 

    	 

    

 

5.5. Licensee
Regulatory Interaction Rights. Notwithstanding Section 5.2 above, interaction with the regulatory agencies in any country,
including, without limitation the FDA, concerning Hydrolyzed Galactomannan of Licensee in the Field of Use shall be exclusively
conducted by Licensee and Licensee shall be the official company sponsor. Subject to Section 5.3(a) hereof, Licensee shall
have complete authority to act as Licensee, in its sole discretion, deems appropriate with respect to any such regulatory matter.

 

5.7. Trademark.
Nothing in this Agreement shall be deemed to grant to Licensee any right to use the trademark “NDPD”, the NDPD corporate
logo, or any other trademark owned by NDPD or its Affiliates.

 

ARTICLE 6

Representations &
Warranties

 

6.1. Organization.
Each party represents and warrants to the other party that such party is a corporation duly organized, validly existing, and in
good standing under the laws of the jurisdiction of its incorporation.

 

6.2. Authorization
of Transaction. Each party represents and warrants to the other party that it has full power and authority (including full
corporate power and authority) to execute and deliver this Agreement and to perform its obligations hereunder. All necessary corporate
proceedings (including any necessary approval by the board of directors) have been taken by such party to duly authorize the execution,
delivery, and performance of this Agreement by such party. This Agreement constitutes the valid and legally binding obligation
of such party, enforceable against such party in accordance with its terms and conditions.

 

6.3. No
Conflicts. NDPD represents and warrants to Licensee that it has not entered into any inconsistent prior obligations concerning
the Subject Technology that would prevent Licensee from exercising the rights being licensed to it hereunder.

 

6.4. No
Claims. NDPD represents and warrants to it has not received written notification from a third party that the manufacture, use,
importation or sale of the License Products under the license granted herein under the Subject Technology will infringe any patents,
copyrights, trade secrets or any other intellectual property rights of any third parties.

 

6.5. Rights
to License. NDPD represents and warranties that it has all rights necessary to enter into this Agreement with Licensee, including,
without limitation, all licenses and assignments from Platt of the Subject Technology required to permit this license to Licensee
under this Agreement.

 

ARTICLE 7

Miscellaneous

 

7.1. Assignment.
Either party may assign or otherwise transfer its rights and obligations under this Agreement to any successor in interest (by
merger, share exchange, combination or consolidation of any type, operation of Law, purchase or otherwise), provided that such
assignee or successor agrees to be bound by the terms hereof, and provided further that in the event of such an assignment by Licensee,
Licensee’s consulting agreement with [*], if any, pursuant to Section 2.6 and Licensee’s right of notice pursuant
to Section 2.7 shall terminate effective upon such transfer and assignment. Except as set forth above, Licensee may not assign
or otherwise transfer its rights and obligations under this Agreement and any attempt to so assign or otherwise transfer its rights
and obligations under this Agreement shall represent a breach of the Agreement.

 

    	6 

    	 

    

 

7.2. Entire
Agreement. This Agreement, together with the Exhibits hereto, the Investor Agreement and the Investors’ Rights Agreement,
constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all previous proposals
or agreements, oral or written, and all negotiations, conversations or discussions heretofore had between the parties related to
the subject matter of this Agreement.

 

7.3. Survival.
Articles 4 and 7 and Section 5.3 shall survive termination or expiration of this Agreement for any reason and continue thereafter
in full force and effect.

 

7.4. Waiver,
Discharge, etc. This Agreement may not be released, discharged, abandoned, changed or modified in any manner, except by an
instrument in writing signed on behalf of each of the parties to this Agreement by their duly authorized representatives. The failure
of either party to enforce at any time any of the provisions of this Agreement shall in no way be construed to be a waiver of any
such provision, nor in any way to affect the validity of this Agreement or any part of it or the right of either party after any
such failure to enforce each and every such provision. No waiver of any breach of this Agreement shall be held to be a waiver of
any other or subsequent breach.

 

7.5. Execution
in Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
agreement, and shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the
other party.

 

7.6. Titles
and Headings: Construction. The titles and headings to Sections herein are inserted for the convenience of reference only and
are not intended to be a part of or to affect the meaning or interpretation of this Agreement. This Agreement shall be construed
without regard to any presumption or other rule requiring construction hereof against the party causing this Agreement to be drafted.

 

7.7. Benefit.
Nothing in this Agreement, expressed or implied, is intended to confer on any person other than the parties to this Agreement or
their respective permitted successors or assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

 

7.8. Notices.
All notices or other communications to a party required or permitted hereunder shall be in writing and shall be delivered personally,
overnight mail or by telecopy (receipt confirmed) to such party (or, in the case of an entity, to an executive officer of such
party) or shall be given by certified mail, postage prepaid with return receipt requested, addressed as follows:

 

if to Licensee, to:

 

Pharmalectin, Inc.

233 Needham St., Ste 300,

Newton, MA 02464

Att: Ola Soderquist

 

and if to NDPD, to:

 

NDPD Pharma, Inc.

233 Needham St., Ste 300,

Newton, MA 02464

Att: David Platt

 

    	7 

    	 

    

 

Licensee or NDPD may change
their respective above-specified recipient and/or mailing address by notice to the other party given in the manner herein prescribed.
All notices shall be deemed given on the day when actually delivered as provided above (if delivered personally or by telecopy)
or on the day shown on the return receipt (if delivered by mail).

 

7.9. Severability.
If any provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining provisions shall nonetheless
be enforceable according to their terms. Further, if any provision is held to be overbroad as written, such provision shall be
deemed amended to narrow its application to the extent necessary to make the provision enforceable according to applicable Law
and shall be enforced as amended.

 

7.10. Governing
Law. This Agreement shall be construed in accordance with Massachusetts law, excluding its choice of law provisions.

 

[Signature Page Follows]

    	8 

    	 

    

 

IN WITNESS WHEREOF, each of
the parties has caused this License Agreement to be executed in the manner appropriate to each, effective as of the date first
above written.

 

 

	
        GRANTOR:

         
	 	
        LICENSEE:

         

	
        NDPD Pharma, Inc.,

        a Nevada corporation

         
	 	
        Pharmalectin, Inc.,

        a Delaware corporation

         

	 	 	 
	By: /s/
    David Platt_____________________	 	By: /s/Ola
    Soderquist_________________
	Name:David Platt                                                  	 	Name:Ola Soderquist                                        
	Title:CEO                                                                	 	Title:CFO                                                             

 

    	9 

    	 

    

Exhibit A

 

Subject Technology

 

 

 

APPLICATION INFORMATION

Application Number: unassigned

Application Type: Provisional

Subject Matter: Utility

Title: Galactomannans for Treatment of SARS COV2
/ COVID-19

Attorney Docket Number:: MDX-P03-01

Small Entity: Yes

 

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]